Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astellas Pharma Inc (ALPMF)

Astellas Pharma Inc (ALPMF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 22.29
  • Price/Book 3.03
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.6700 +20.01%
on 01/27/26
17.3900 -5.66%
on 02/13/26
+3.0550 (+22.88%)
since 01/12/26
3-Month
11.4001 +43.90%
on 11/24/25
17.3900 -5.66%
on 02/13/26
+4.2050 (+34.47%)
since 11/20/25
52-Week
8.4050 +95.18%
on 04/11/25
17.3900 -5.66%
on 02/13/26
+6.7100 (+69.21%)
since 02/20/25

Most Recent Stories

More News
Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Astellas...

ALPMF : 16.4050 (+6.32%)
Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)

In a report released today, Miki Sogi from Bernstein maintained a Hold rating on Astellas Pharma, with a price target of Yen1,600.00. The company’s shares closed last Friday at $11.10.Elevate Your Investing...

ALPMY : 15.9600 (+0.19%)
ALPMF : 16.4050 (+6.32%)
Why Shares of Adaptive Biotechnologies Jumped This Week

The company could see its first FDA-approved therapy as early as next year.

ALPMF : 16.4050 (+6.32%)
ADPT : 15.39 (+1.25%)

Business Summary

Astellas Pharma Inc was incorporated on March 20, 1939. The Company and its subsidiaries are engaged in the manufacturing, marketing of pharmaceuticals products. It develops products in the areas of urology, immunology and allergy, cardiovascular, diabetes, gastrointestinal and motor organs. Its products...

See More

Key Turning Points

3rd Resistance Point 16.4050
2nd Resistance Point 16.4050
1st Resistance Point 16.4050
Last Price 16.4050
1st Support Level 16.4050
2nd Support Level 16.4050
3rd Support Level 16.4050

See More

52-Week High 17.3900
Last Price 16.4050
Fibonacci 61.8% 13.9577
Fibonacci 50% 12.8975
Fibonacci 38.2% 11.8373
52-Week Low 8.4050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar